The results were featured at the American Society of Haematology (ASH) annual meeting and, according to GSK, "support the potential ... treatment for the blood cancer. After being all but written ...

By sharing the stories of EDI champions in science, we hope to shed light on both the importance of diversity and the ...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical ... $1.5 billion from GSK, which licensed in an early stage ovarian and endometrial cancer drug, HS-20089 ...

Breast Cancer has impacted every group, but according to the American Cancer Society, Black women are more at risk.

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

The company has placed a strong emphasis on expanding its cancer drug portfolio and specialty medicines. However, GSK's latest financial report comes amid a barrage of lawsuits, including a major ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...